Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors

Study Summary

The purpose of the study is to investigate the safety and effectiveness of Alhemo® in all participants under real-world clinical practice in Japan. Participants will get Alhemo® as prescribed by the study doctor. The study will last for about 2 years.

Conditions

Haemophilia A Haemophilia B

Interventions / Drugs

Concizumab

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment23 participants

Primary Completion—

Lead SponsorNovo Nordisk A/S

Data Retrieved2026-04-11 02:55:47.366518+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.